Erratum: Discovery of the First Thumb Pocket 1 NS5B Polymerase Inhibitor (BILB 1941) with Demonstrated Antiviral Activity in Patients Chronically Infected with Genotype 1 Hepatitis C Virus (HCV) (Journal of Medicinal Chemistry (2012) 55:17 (7650-7666) DOI: 10.1021/jm3006788);Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV)

Journal of Medicinal Chemistry

Volumn 55, Issue 17, 2012, Pages 7650-7666

  Beaulieu, Pierre L ^a   Bös, Michael ^a   Cordingley, Michael G ^a   Chabot, Catherine ^a   Fazal, Gulrez ^a   Garneau, Michel ^a   Gillard, James R ^a   Jolicoeur, Eric ^a   Laplante, Steven ^a   McKercher, Ginette ^a   Poirier, Martin ^a   Poupart, Marc André ^a   Tsantrizos, Youla S ^a   Duan, Jianmin ^a   Kukolj, George ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 [[1 [(3 CYCLOPENTYL 1 METHYL 2 PYRIDIN 2 YL 1H INDOLE 6 CARBONYL)AMINO]CYCLOBUTANECARBONYL]AMINO]PHENYL]ACRYLIC ACID; ANTIVIRUS AGENT; BILB 1941; RNA DIRECTED RNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CRYSTAL STRUCTURE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; IC 50; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; RAT;

EID: 84866332769     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501225c     Document Type: Erratum

References (78)

1. Choo, Q.-L.; Kuo, G.; Weiner, A. J.; Overby, L.R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 1989, 244, 359-362 (Pubitemid 19117877)
2. Lavanchy, D. Evolving epidemiology of hepatitis C virus Clin. Microbiol. Infect. 2011, 17, 107-115
3. Simmonds, P. Genetic diversity and evolution of hepatitis C virus-15 years on J. Gen. Virol. 2004, 85, 3173-3188 (Pubitemid 39445434)
4. Wise, M.; Bialek, S.; Finelli, L.; Bell, B.; Sorvillo, F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004 Hepatology 2008, 47, 1128-1135 (Pubitemid 351547899)
5. Davis, G. L.; Albright, J. E.; Cook, S. F.; Rosenberg, D. M. Projecting future complications of chronic hepatitis C in the United States Liver Transplant. 2003, 9, 331-338 (Pubitemid 36443043)
6. Bosetti, C.; Levi, F.; Lucchini, F.; Zatonski, W. A.; Negri, E.; La Vecchia, C. Worldwide mortality from cirrhosis: an update to 2002 J. Hepatol. 2007, 46, 827-839 (Pubitemid 46529045)
7. Wise, M.; Bialek, S.; Finelli, L.; Bell, B. P.; Sorvillo, F. Changing trends in hepatitis C-related mortality in the United States Hepatology 2008, 47, 1128-1135 (Pubitemid 351547899)
8. Davila, J. A.; Morgan, R. O.; Shaib, Y.; McGlynn, K. A.; El-Serag, H. B. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study Gastroenterology 2004, 127, 1372-1380 (Pubitemid 39457763)
9. Fried, M. W.; Shiffman, M. L.; Reddy, K. R.; Smith, C.; Marinos, G.; Gonçales, F. L., Jr.; Haüssinger, D.; Diago, M.; Carosi, G.; Dhumeaux, D.; Craxi, A.; Lin, A.; Hoffman, J.; Yu, J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N. Engl. J. Med. 2002, 347, 975-982
10. Zeuzem, S.; Berg, T.; Moeller, B.; Hinrichsen, H.; Mauss, S.; Wedemeyer, H.; Sarrazin, C.; Hueppe, D.; Zehnter, E.; Manns, M. P. Expert opinion on the treatment of patients with chronic hepatitis C J. Viral Hepatitis 2009, 16, 75-90
11. National Institutes of Health consensus development conference statement: management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002, 123, 2082-2099.
12. Manns, M. P.; Foster, G. R.; Rockstroh, J. K.; Zeuzem, S.; Zoulim, F.; Houghton, M. The way forward in HCV treatment-finding the right path Nat. Rev. Drug Discovery 2007, 6, 991-1000 (Pubitemid 350201789)
13. Björnsson, E.; Verbaan, H.; Oksanen, A.; Frydén, A.; Johansson, J.; Friberg, S.; Dalgård, O.; Kalaitzakis, E. Health-related quality of life in patients with different stages of liver disease induced by hepatitis C Scand. J. Gastroenterol. 2009, 44, 878-887
14. Lohmann, V.; Körner, F.; Koch, J. O.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 1999, 285, 110-113 (Pubitemid 29307577)
15. Wakita, T.; Pietschmann, T.; Kato, T.; Date, T.; Miyamoto, M.; Zhao, Z.; Murthy, K.; Habermann, A.; Kräusslich, H.-G.; Mizokami, M.; Bartenschlager, R.; Liang, T. G. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome Nat. Med. 2005, 11, 791-796 (Pubitemid 41021213)
16. Lindenbach, B. D.; Evans, M. J.; Syder, A. J.; Wölk, B.; Tellinghuisen, T. L.; Liu, C. C.; Maruyama, T.; Hynes, R. O.; Burton, D. R.; McKeating, J. A.; Rice, C. M. Science 2005, 309, 623-626
17. Tan, S.-L.; He, Y. Hepatitis C: Antiviral Drug Discovery and Development; Caister Academic Press: Norwich, U.K., 2011.
18. Lindenbach, B. D.; Rice, C. M. Unraveling hepatitis C virus replication from genome to function Nature 2005, 436, 933-938 (Pubitemid 41191668)
19. Hinrichsen, H.; Benhamou, Y.; Wedemeyer, H.; Reiser, M.; Sentjens, R. E.; Calleja, J. L.; Forns, X.; Erhardt, A.; Cröenlein, J.; Chaves, R.; Yong, C. -L.; Nehmiz, G.; Steinmann, G. G. Short-term antiviral efficacy of BILN 2061, a HCV serine protease inhibitor, in hepatitis C genotype 1 patients Gastroenterology 2004, 127, 1347-1355 (Pubitemid 39457761)
20. Lamarre, D.; Anderson, P. C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Bös, M.; Cameron, D. R.; Cartier, M.; Cordingley, M. G.; Faucher, A.-M.; Goudreau, N.; Kawai, S. H.; Kukolj, G.; Lagacé, L.; LaPlante, S. R.; Narjes, H.; Poupart, M.-A.; Rancourt, J.; Sentjens, R. E.; St George, R.; Simoneau, B.; Steinmann, G.; Thibeault, D.; Tsantrizos, Y.; Weldon, S. M.; Yong, C.-L.; Llinàs-Brunet, M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus Nature 2003, 426, 186-189 (Pubitemid 37442587)
21. Gentile, I.; Carleo, M. A.; Borgia, F.; Castaldo, G.; Borgia, G. The efficacy and safety of telaprevir: a new protease inhibitor against hepatitis C virus Expert Opin. Invest. Drugs 2010, 19, 151-159
22. Kwong, D. A.; Kauffman, R. S.; Mueller, P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus Nat. Biotechnol. 2011, 29, 993-1003
23. Berman, K.; Kwo, P. Y. Boceprevir, an NS3 protease inhibitor of HCV Clin. Liver Dis. 2009, 13, 429-439
24. Asselah, T.; Marcellin, P. New direct-acting antivirals combination for the treatment of chronic hepatitis C Liver Int. 2011, 31, 68-77
25. Sarrazin, C.; Zeuzem, S. Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 2010, 138, 447-462
26. Gaudieri, S.; Rauch, A.; Pfafferott, K.; Barnes, E.; Cheng, W.; McCaughan, G.; Shackel, N.; Jeffrey, G. P.; Mollison, L.; Baker, R.; Furrer, H.; Günthard, H. F.; Freitas, E.; Humphreys, I.; Klenerman, P.; Mallal, S.; James, I.; Roberts, S.; Nolan, D.; Lucas, M. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy Hepatology 2009, 49, 1069-1082
27. White, P. W.; Llinàs-Brunet, M.; Amad, M.; Bethell, R. C.; Bolger, G.; Cordingley, M. G.; Duan, J.; Garneau, M.; Lagacé, L.; Thibeault, D.; Kukolj, G. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease Antimicrob. Agents Chemother. 2010, 54, 4611-4618
28. Lin, T.-I.; Lenz, O.; Fanning, G.; Verbinnen, T.; Delouvroy, F.; Scholliers, A.; Vermeiren, K.; Rosenquist, Å.; Edlund, M.; Samuelsson, B.; Vrang, L.; de Kock, H.; Wigerinck, P.; Raboisson, P.; Simmen, K. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor Antimicrob. Agents Chemother. 2009, 53, 1377-1385
29. Soriano, V. A new era for hepatitis C-new diagnostics tools and new weapons ACS Med. Chem. Lett. 2012, 3, 440-441
30. Gane, D. Future hepatitis C virus treatment: interferon-sparing combinations Liver Int. 2011, 31, 62-67
31. Cordek, D. G.; Bechtel, J. T.; Maynard, A. T.; Kazmierski, W. M.; Cameron, C. E. Targeting the NS5A protein on HCV: an emerging option Drugs Future 2011, 36, 691-711
32. Sulkowski, M.; Gardiner, D.; Lawitz, E.; Hinestrosa, F.; Nelson, D.; Thuluvath, P.; Rodriguez-Torres, M.; Lok, A.; Schwartz, H.; Reddy, K. R.; Eley, T.; Wind-Rotolo, M.; Huang, J.-P.; Gao, M.; McPhee, F.; Hindes, R.; Symonds, B.; Pasquinelli, C.; Grasela, D. Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), ± ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3 J. Hepatol. 2012, 56 (Suppl. 2) S560
33. Kolykhalov, A. A.; Mihalik, K.; Feinstone, S. M.; Rice, C. M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′-nontranslated region are essential for virus replication in vivo J. Virol. 2000, 74, 2046-2051 (Pubitemid 30434065)
34. Chinnaswamy, S.; Yarbrough, I.; Palaninathan, S.; Kumar, C. T. R.; Vijayaraghavan, V.; Demeler, B.; Lemon, S. M.; Sacchettini, J. C.; Kao, C. C. A locking mechanism regulates RNA synthesis and host protein interaction by the hepatitis C virus polymerase J. Biol. Chem. 2008, 283, 20535-20546
35. Harrus, D.; Ahmed-El-Sayed, N.; Simister, P. C.; Miller, S.; Triconnet, M.; Hagedorn, C. H.; Mahias, K.; Rey, F. A.; Astier-Gin, T.; Bressanelli, S. Further insights into the roles of GTP and the C-terminus of the hepatitis C virus polymerase in the initiation of RNA synthesis J. Biol. Chem. 2010, 285, 32906-32918
36. Bressanelli, S.; Tomei, L.; Roussel, A.; Incitti, I.; Vitale, R. L.; Mathieu, M.; De Francesco, R.; Rey, F. A. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 13034-13039
37. Beaulieu, P. L. Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection Expert Opin. Ther. Pat. 2009, 19, 145-164
38. Watkins, W. J.; Ray, A. S.; Chong, L. S. HCV NS5B polymerase inhibitors Cur. Opin. Drug Discovery Dev. 2010, 13, 441-465
39. Sofia, M. J.; Chang, W.; Furman, P. A.; Mosley, R. T.; Ross, B. S. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase J. Med. Chem. 2012, 55, 2532-2531
40. Brown, N. A. Progress towards improving antiviral therapy for hepatitis C virus polymerase inhibitors. Part 1: nucleoside analogues Expert Opin. Invest. Drugs 2009, 18, 709-725
41. Furman, P. A.; Lam, A. M.; Murakami, E. Nucleoside analog inhibitors of hepatitis C virus replication: recent advances, challenges and trends Future Med. Chem. 2009, 1, 1429-1452
42. Sofia, M. J. Nucleotide prodrugs for HCV therapy Antiviral Chem. Chemother. 2011, 22, 23-49
43. Le Pogam, S.; Jiang, W.-R.; Leveque, V.; Rajyaguru, S.; Ma, H.; Kang, H.; Jiang, S.; Singer, M.; Ali, S.; Klumpp, K.; Smith, D.; Symons, J.; Cammack, N.; Nájera, I. In vitro selected Con1 subgenomic replicons resistant to 2′- C -methyl-cytidine or to R1479 show lack of cross-resistance Virology 2006, 351, 340-348
44. McCown, M. F.; Rajyaguru, S.; Le Pogam, S.; Ali, S.; Jiang, W.-R.; Kang, H.; Symons, J.; Cammack, N.; Nájera, I. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to non-nucleoside polymerase or protease inhibitors Antimicrob. Agents Chemother. 2008, 52, 1604-1612 (Pubitemid 351614649)
45. Le Pogam, S.; Seshaadri, A.; Ewing, A.; Kang, H.; Kosaka, A.; Yan, J.-M.; Berrey, M.; Symonds, B.; DeLaRosa, A.; Cammack, N.; Nájera, I. RG1728 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients J. Infect. Dis. 2010, 202, 1510-1519
46. Gane, E. J.; Roberts, S. K.; Stedman, C. A. M.; Angus, Q. W.; Ritchie, B.; Elston, R.; Ipe, D.; Morcos, P. N.; Baher, L.; Nájera, I.; Chu, T.; Lopatin, U.; Berrey, M. M.; Bradford, W.; Laughlin, M.; Shulman, N. S.; Smith, P. F. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomized, double-blind, placebo-controlled, dose-escalation trial Lancet 2010, 376, 1467-1475
47. Chinnaswamy, S.; Murali, A.; Li, P.; Fujisaki, K.; Kao, C. C. Regulation of de novo-initiated RNA synthesis in hepatitis C virus RNA-dependent RNA polymerase by intermolecular interactions J. Virol. 2010, 84, 5923-5935
48. Rigat, K.; Wang, Y.; Hudyma, T. W.; Ding, M.; Zheng, X.; Gentles, R. G.; Beno, B. R.; Gao, M.; Roberts, S. B. Ligand-induced changes in hepatitis C virus NS5B polymerase structure Antiviral Res. 2010, 88, 197-206
49. Li, H.; Shi, S. T. Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges Future Med. Chem. 2010, 2, 121-141
50. Sofia, M. J.; Furman, P. A.; Symonds, W. T. 2′- F -2′- C -Methyl Nucleosides and Nucleotides for the Treatment of Hepatitis C Virus: From Discovery to the Clinic. In Accounts in Drug Discovery: Case Studies in Medicinal Chemistry; Barrish, J. C.; Carter, P. H.; Cheng, P. T. W.; Zhaler, R., Eds.; Royal Society of Chemistry: Cambridge, U.K., 2010; Vol. 4, pp 238-266.
51. Zhou, X. J.; Pietropaolo, K.; Chen, J.; Khan, S.; Sullivan-Bolyai, J.; Mayers, D. Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects Antimicrob. Agents Chemother. 2011, 55, 76-81
52. Sofia, M. J.; Bao, D.; Chang, W.; Du, J.; Nagaratham, D.; Rachakonda, S.; Reddy, P. G.; Ross, B. S.; Wang, P.; Zhang, H.-R.; Bansal, S.; Espiritu, C.; Keilman, M.; Lam, A. M.; Steuer, H. M. M.; Niu, C.; Otto, M. J.; Furman, P. A. Discovery of a β- d -2′-deoxy-2′-α-fluoro-2′- β- C -methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus J. Med. Chem. 2010, 53, 7202-7218
53. McGuigan, C.; Madela, K.; Aljarah, M.; Gilles, A.; Brancale, A.; Zonta, N.; Chamberlain, S.; Vernachio, J.; Hutchins, J.; Hall, A.; Ames, B.; Gorovits, E.; Ganguly, B.; Kolykhalov, A.; Wang, J.; Muhammad, J.; Patti, J. M.; Henson, G. Design, synthesis and evaluation of a novel double prodrug: INX-08189. A new clinical candidate for hepatitis C virus Bioorg. Med. Chem. Lett. 2010, 20, 4850-4854
54. Kadow, J. F.; Gentles, R.; Ding, M.; Bender, J.; Bergstrom, C.; Grant-Young, K.; Hewawasam, P.; Hudyma, T.; Martin, S.; Nickel, A.; Regueiro-Ren, A.; Tu, Y.; Yang, Z.; Yeung, K.-S.; Zheng, X.; Chen, B.-C.; Chao, S.; Sun, J.-H.; Li, J.; Mathur, A.; Smith, D.; Wu, D.-R.; Beno, B.; Hanumegowda, U.; Knipe, J.; Parker, D. D.; Zhuo, X.; Lemm, J.; Liu, M.; Pelosi, L.; Rigat, K.; Voss, S.; Wang; Y.; Wang, Y.-K.; Colonno, R.; Gao, M.; Roberts, S. B.; Meanwell, N. A. Discovery of BMS-791325, an Allosteric NS5B Replicase Inhibitor for the Treatment of Hepatitis C. Presented at the 243rd National Meeting of the American Chemical Society, San Diego, CA, March 25-29, 2012; MEDI-23.
55. Vendeville, S.; Lin, T.-I.; Hu, L.; Tahn, A.; MgGowan, D.; Cummings, M. D.; Amssoms, K.; Last, S.; Devogelaere, B.; Rouan, M.-C.; Vigen, L.; Berke, J. M.; Dehertogh, P.; Fransen, E.; Cleiren, E.; van der Heim, L.; Fanning, G.; Van Emeien, K.; Nyanguile, O.; Simmen, K.; Raboisson, P. Discovery of the Clinical Candidate TMC 647055, a Non-Nucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase. Presented at the 18th International Symposium on Hepatitis C Virus and Related Viruses, Seattle, WA, Sept 8-12, 2011; Abstract P1.33.
56. Rosario, M.; Chauret, N.; George, S.; Kieffer, T. L.; Koziel, M. J.; Nicolas, O.; Proulx, L. Therapies for Treating Hepatitis C Virus Infection. Patent WO 2011/094489, August 4, 2011.
57. Li, H.; Tatlock, J.; Linton, A.; Gonzalez, J.; Jewell, T.; Patel, L.; Ludlum, S.; Drowns, M.; Rahavendran, S. V.; Skor, H.; Hunter, R.; Shi, S. T.; Herlihy, K. J.; Parge, H.; Hickey, M.; Yu, X.; Chau, F.; Nonomiya, J.; Lewis, C. Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7- dimethyl-[1,2,4]triazolo[1,5, a ]-pyrimidin-2-yl)methyl-4-hydroxy-5,6- dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor J. Med. Chem. 2009, 52, 1255-1258
58. Tran, C. V.; Ruebsam, F.; Murphy, D. E.; Dragovich, P.; Zhou, Y.; Chen, L.; Kuccera, D. 5,6-Dihydro-1 H -pyridin-2-one compounds. Patent 7,939,524, May 10, 2011, (see also www.ama-assn.org/resources/doc/usan/lomibuvir.pdf).
59. McKercher, G.; Beaulieu, P. L.; Lamarre, D.; LaPlante, S.; Lefebvre, S.; Pellerin, C.; Thauvette, L.; Kukolj, G. Specific inhibitors of HCV polymerase identified using a NS5B with lower affinity for template/primer substrate Nucleic Acids Res. 2004, 32, 422-431 (Pubitemid 38268075)
60. Beaulieu, P. L.; Bös, M.; Bousquet, Y.; Fazal, G.; Gauthier, J.; Gillard, J.; Goulet, S.; LaPlante, S.; Poupart, M.-A.; Lefebvre, S.; McKercher, G.; Pellerin, C.; Austel, V.; Kukolj, G. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives Bioorg. Med. Chem. Lett. 2004, 14, 119-124 (Pubitemid 38016210)
61. Beaulieu, P. L. Finger loop inhibitors of the HCV NS5B polymerase: discovery and prospects for new HCV therapy Cur. Opin. Drug Discovery Dev. 2006, 9, 618-626 (Pubitemid 44378830)
62. Hirashima, S.; Suzuki, T.; Ishida, T.; Noji, S.; Yata, S.; Ando, I.; Komatsu, M.; Ikeda, S.; Hashimoto, H. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109 J. Med. Chem. 2006, 49, 4721-4736 (Pubitemid 44162700)
63. Narjes, F.; Crescenzi, B.; Ferrara, M.; Habermann, J.; Colarusso, S.; del Rosario, M.; Ferreira, R.; Stansfield, I.; Mackay, A. C.; Conte, I.; Ercolani, C.; Zaramella, S.; Palumbi, M.-C.; Meuleman, P.; Leroux-Roels, G.; Guiliano, C.; Fiore, F.; Di Marco, S.; Baiocco, P.; Koch, U.; Migliaccio, G.; Altamura, S.; Laufer, R.; De Francesco, R.; Rowley, M. Discovery of (7 R)-14-cyclohexyl-7-{[2- (dimethylamino)ethyl](methyl)amino}-7,8-dihydro-6 H -indolo[1,2- e ][1,5]benzoxazocine-1-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase J. Med. Chem. 2011, 54, 289-301
64. Zheng, X.; Hudyma, T. W.; Martin, S. W.; Bergstrom, C.; Ding, M.; He, F.; Romine, J.; Poss, M. A.; Kadow, J. F.; Chang, C.-H.; Wan, J.; Witmer, M. R.; Morin, P.; Camac, D. M.; Sheriff, S.; Beno, B. R.; Rigat, K. L.; Wang, Y.-K.; Fridell, F.; Lemm, J.; Qiu, D.; Liu, M.; Voss, S.; Pelosi, L.; Roberts, S. B.; Gao, M.; Knipe, J.; Gentles, R. G. Syntheses and intitial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus Bioorg. Med. Chem. Lett. 2011, 21, 2925-2929
65. Beaulieu, P. L.; Bös, M.; Bousquet, Y.; DeRoy, P.; Fazal, G.; Gauthier, J.; Gillard, J.; Goulet, S.; McKercher, G.; Poupart, M.-A.; Valois, S.; Kukolj, G. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency Bioorg. Med. Chem. Lett. 2004, 14, 967-971 (Pubitemid 38167623)
66. Beaulieu, P. L.; Bousquet, Y.; Gauthier, J.; Gillard, J.; Marquis, M.; McKercher, G.; Pellerin, C.; Valois, S.; Kukolj, G. Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells J. Med. Chem. 2004, 47, 6884-6892 (Pubitemid 40053776)
67. LaPlante, S. R.; Jakalian, A.; Aubry, N.; Bousquet, Y.; Ferland, J.-M.; Gillard, J.; Lefebvre, S.; Poirier, M.; Tsantrizos, Y. S.; Kukolj, G.; Beaulieu, P. L. Binding mode determination of benzimidazole inhibitors of the hepatitis C virus RNA polymerase by a structure and dynamics startegy Angew. Chem., Int. Ed. 2004, 43, 4306-4311 (Pubitemid 39257407)
68. Goulet, S.; Poupart, M.-A.; Gillard, J.; Poirier, M.; Kukolj, G.; Beaulieu, P. L. Discovery of benzimidazole-diamide finger loop (thumb pocket 1) allosteric inhibitors of HCV NS5B polymerase: implementing parallel synthesis for rapid linker optimization Bioorg. Med. Chem. Lett. 2010, 20, 196-200
69. Kukolj, G.; McGibbon, G. A.; McKercher, G.; Marquis, M.; Lefèbvre, S.; Thauvette, L.; Gauthier, J.; Goulet, S.; Poupart, M.-A.; Beaulieu, P. L. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase J. Biol. Chem. 2005, 280, 39260-39267 (Pubitemid 41713879)
70. Beaulieu, P. L.; Gillard, J.; Jolicoeur, E.; Duan, J.; Garneau, M.; Kukolj, G.; Poupart, M.-A. From benzimidazole to indole 5-carboxamide thumb pocket 1 inhibitors of HCV NS5B polymerase. Part 1: Indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons Bioorg. Med. Chem. Lett. 2011, 21, 3658-3663
71. Beaulieu, P. L.; Chabot, C.; Duan, J.; Garneau, M.; Gillard, J.; Jolicoeur, E.; Poirier, M.; Poupart, M.-A.; Stammers, T. A.; Kukolj, G.; Tsantrizos, Y. S. Indole 5-carboxamide thumb pocket 1 inhibitors of HCV NS5B polymerase with nanomolar potency in cell-based subgenomic replicons (part 2): central amino acid linker and right-hand-side SAR studies Bioorg. Med. Chem. Lett. 2011, 21, 3664-3670
72. LaPlante, S. R.; Gillard, J. R.; Jakalian, A.; Aubry, N.; Coulombe, R.; Brochu, C.; Tsantrizos, Y. S.; Poirier, M.; Kukolj, G.; Beaulieu, P. L. Importance of ligand bioactive conformation in the discovery of potent indole-diamide inhibitors of the hepatitis C virus NS5B J. Am. Chem. Soc. 2010, 132, 15204-15212
73. Erhardt, A.; Deterding, K.; Benhamou, Y.; Reiser, M.; Forns, X.; Pol, S.; Calleja, J. L.; Ross, S.; Spangenberg, H. C.; Garcia-Samaniego, J.; Fuchs, M.; Enriquez, J.; Wiegand, J.; Stern, J.; Wu, K.; Kukolj, G.; Marquis, M.; Beaulieu, P.; Nehmiz, G.; Steffgen, J. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment Antiviral Ther. 2009, 14, 23-32
74. Beaulieu, P. L.; Gillard, J.; Bykowski, D.; Brochu, C.; Dansereau, N.; Duceppe, J.-S.; Haché, B.; Jakalian, A.; Lagacé, L.; LaPlante, S.; McKercher, G.; Moreau, E.; Perreault, S.; Stammers, T.; Thauvette, L.; Warrington, J.; Kukolj, G. Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds Bioorg. Med. Chem. Lett. 2006, 16, 4987-4993 (Pubitemid 44247718)
75. Vernin, G. In Thiazole and Its Derivatives; Metzger, J. V., Ed.; Wiley: New York, 1979; Part 1, Chapter 2.
76. Paik, S.; Kwak, H. S.; Park, T. H. A facile synthesis of (-)-cucurbitine Bull. Korean Chem. Soc. 2000, 21, 131-132
77. Rorrer, L. C.; Hopkins, S. D.; Connors, M. K.; Lee, D. W., III; Smith, M. V.; Rhodes, H. J.; Uffelman, E. S. A convenient new route to tetradentate and pentadentate macrocyclic tetraamide ligands Org. Lett. 1999, 1, 1157-1159
78. Beaulieu, P. L.; Fazal, G.; Goulet, S.; Kukolj, G.; Poirier, M.; Tsantrizos, Y.; Jolicoeur, E.; Gillard, J.; Poupart, M.-A.; Rancourt, J. Patent WO 03/010141, 2003.